Business Context and Reporting Period
Company: Humacyte, Inc. (HUMA)
Filing Type: Form 8-K (Current Report)
Date of Report: December 16, 2025
Event: Entry into a Material Definitive Agreement (Sales Agreement) with TD Securities (USA) LLC ("TD Cowen").
Key Financial Metrics
This filing does not contain audited financial statements, revenue, profit, cash flow, or debt metrics. The primary financial data point disclosed is the potential capital raise:
- Maximum Offering Size: Up to $60,000,000 in aggregate offering price.
- Commission Fee: Up to 3.0% of gross proceeds payable to TD Cowen.
- Securities Involved: Common Stock (par value $0.0001) and Redeemable Warrants (HUMAW, exercise price $11.50).
Material Changes
The filing announces the establishment of an "at-the-market" (ATM) equity offering facility. This represents a new mechanism for the Company to raise capital, distinct from prior periods where no such specific agreement with TD Cowen was in place. The Company is not obligated to sell any shares under this agreement.
Guidance, Outlook, and Management Commentary
Use of Proceeds: The Company intends to use net proceeds, if any, for the following purposes:
- Commercialization of Symvess® in the vascular trauma indication.
- Development of product candidates in the Company's pipeline.
- Working capital and general corporate purposes.
Sales Method: Shares may be sold directly on or through Nasdaq, through other existing trading markets, or to market makers. TD Cowen will act as agent and use commercially reasonable efforts to sell shares based on Company instructions.
Termination: The agreement terminates upon the sale of all shares or earlier termination by either party with ten days' prior notice (or immediately by TD Cowen under certain material adverse effect circumstances).
Investor Verification Checklist
- Verify the current market price of HUMA common stock to assess potential dilution impact of a $60 million offering.
- Review the effective Registration Statement (File No. 333-290231) filed on September 12, 2025, for detailed risk factors.
- Monitor subsequent filings for actual share sales volumes and proceeds generated under this agreement.
- Confirm the Company's current cash position and burn rate to evaluate the necessity of this capital raise.
- Check for any material adverse effect clauses that could trigger immediate termination by the agent.